Premium
Controversy still swirls around FDA user fees: Since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals—but does speed equal safety?
Author(s) -
Ullman Kurt
Publication year - 2013
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.24045
Subject(s) - medical prescription , citation , prescription drug , drug , medicine , library science , computer science , pharmacology
Eteplirsen for the treatment of Duchenne muscular dystrophy (pages 637–647) Jerry R. Mendell, Louise R. Rodino-Klapac, Zarife Sahenk, Kandice Roush, Loren Bird, Linda P. Lowes, Lindsay Alfano, Ann Maria Gomez, Sarah Lewis, Janaiah Kota, Vinod Malik, Kim Shontz, Christopher M. Walker, Kevin M. Flanigan, Marco Corridore, John R. Kean, Hugh D. Allen, Chris Shilling, Kathleen R. Melia, Peter Sazani, Jay B. Saoud and Edward M. Kaye, the Eteplirsen Study Group